Myelin suppresses plasticity in the mature brain

September 29, 2005

New Haven, Conn.-Yale School of Medicine researchers report in Science this week genetic evidence for the hypothesis that myelination, or formation of a protective sheath around a nerve fiber, consolidates neural circuitry by suppressing plasticity in the mature brain.

This finding has implications for research on restoring mobility to people who have lost motor functions due to spinal cord injury, multiple sclerosis, Lou Gehrig's disease, and other central nervous system disorders.

"The failure of surviving neurons to reestablish functional connection is most obvious after spinal cord injury, but limited nerve cell regeneration and plasticity is central to a range of neurological disorders, including stroke, head trauma, multiple sclerosis, and neurodegenerative disease," said senior author Stephen Strittmatter, professor in the Departments of Neurology and Neurobiology. "Recovery of motor function after serious damage to the mature brain is facilitated by structural and synaptic plasticity."

Strittmatter's laboratory studies how myelin in the central nervous system physically limits axonal growth and regeneration after traumatic and ischemic injury, when blood supply is cut off. A physiological role for the myelin inhibitor pathway has not been defined.

Blocking vision in one eye normally alters ocular dominance in the cortex of the brain only during a critical developmental period, or 20 to 32 days postnatal in mice. Strittmatter's lab, working in collaboration with Nigel Daw, M.D., professor of ophthalmology and neuroscience, and his group, found that mutations in the Nogo-66 receptor (NgR) affect plasticity of ocular dominance. In mice with altered NgR, plasticity during the critical period is normal, but it continues abnormally so that ocular dominance later in development is similar to the plasticity of juvenile stages.
-end-
Science (September 30, 2005)

Yale University

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.